PDMR Dealing

RNS Number : 0688J
Oncimmune Holdings PLC
07 April 2020
 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

PDMR Dealing

 

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has been notified that Matthew Hall, PDMR and Chief Financial Officer, has purchased 9,487 ordinary shares of £0.01 each in the Company ("Ordinary Shares") for £0.527 per share on 7 April 2020.

 

Following this transaction, Matthew has a total interest in the Company of 9,487 Ordinary Shares, representing approximately 0.01 per cent of the Company's issued Ordinary Share capital.    

 

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 


 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Matthew Hall

2

 

Reason for the notification

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 



Identification code

ISIN: GB00BYQ94H38



b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)







Price

Volume




£0.527

9,487







d)

 

Aggregated information




- Aggregated volume

Same as above



- Price




e)

 

Date of the transaction

 

7 April 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

For further information:

Oncimmune Holdings plc

Andrew Stewart, General Counsel and Company Secretary

contact@oncimmune.com    

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHKKOBQKBKDKQK
UK 100